Triple immunosuppression with or without basiliximab in pediatric renal transplantation: Acute rejection rates at one year

Duzova A., Buyan N., Bakkaloglu M., Dalgic A., Soylemezoglu O., Besbas N., ...More

TRANSPLANTATION PROCEEDINGS, vol.35, no.8, pp.2878-2880, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 8
  • Publication Date: 2003
  • Doi Number: 10.1016/j.transproceed.2003.10.087
  • Journal Name: TRANSPLANTATION PROCEEDINGS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2878-2880
  • Hacettepe University Affiliated: Yes

Abstract

Acute rejection (AR) is a major determinant of chronic allograft dysfunction and graft survival. This study evaluated the effect of basiliximab on AR in pediatric renal transplantation on triple immunosuppression. Forty-three transplantations (25 males and 18 females; mean age 14.9 +/- 3.6 years) were performed between 1996 and 2002. Thirteen of the grafts came from cadaveric donors and 30 from living-related donors. All patients were placed on immunosuppression with prednisolone + (azathioprine or mycophenolate mofetil) + (cyclosporine [CYA] or tacrolimus). Basiliximab was also administered in 20 cases. The respective rates of biopsy-proven AR in the basiliximab group (BG) and the standard-regimen group (N-BG) were 0% vs 17.4% (P > .05) at 1 month posttransplantation; 0% vs 26.1% (P < .05) at 3 months; 0% vs 26.1% (P < .05) at 6 months, and 7.1% vs 26.1% (P > .05) at 12 months. In the N-BG group the 1- and 3-year graft survival rates were 91.3% (21/23) and 83.3% (15/18), respectively. The mean glomerular filtration rate (GFR) in the first year after the transplantation was 75 +/- 33 mL/min/1.73 m(2) in the N-BG and 98 +/- 21 mL/min/1.73 m(2) in the BG patients (P < .05).